FDA Brief

Warning letters Drugs

FDA warning letter to

SnugZ USA, Inc.

High riskIssued Sep 28Posted Oct 20Center for Drug Evaluation and Research (CDER)

SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

What happened

FDA inspected SnugZ USA's drug manufacturing facility in West Jordan, Utah, from April 27 to May 1, 2026, and reviewed the company's May 22, 2026, response to the inspection findings (Form FDA 483). The agency found the firm repeatedly retested out-of-specification chemical and microbiological results, or prepared new samples, until analysts got a passing result, then used those results to release OTC drug products to market without a proper investigation. FDA also found incoming components were not adequately identity tested, supplier certificates of analysis were accepted without confirmatory testing, and the quality unit did not exercise its authority; similar violations were cited at an April 1, 2022, regulatory meeting.

What FDA found

  1. The firm did not properly investigate batches or components that failed to meet specifications, and instead retested failing samples until they passed and then shipped the product.

    21 CFR 211.192
  2. Complaint investigations were mostly email exchanges with no real root cause work and no effective corrective and preventive actions.

    21 CFR 211.192
  3. Test methods and standard operating procedures allowed repeated retesting after a failure without investigation, including switching to a second microbiological test instrument to get a passing result.

    21 CFR 211.160(b)
  4. The firm did not test at least one sample of each incoming component lot to confirm identity and did not periodically verify that suppliers' certificates of analysis were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The quality unit did not ensure adequate document control, cleaning validation, annual product quality reviews, complete batch production records, or review of deviations and failing results before release.

    21 CFR 211.22

What FDA wants

FDA tells the firm to hire a qualified CGMP consultant to audit its whole operation, run independent reviews of its investigations, laboratory, complaint and supplier programs, and send a written response to CDER within 15 business days.

Who should pay attention

  • brands and marketers that buy OTC promotional products from this contract manufacturer
  • distributors and retailers selling these OTC drug products
  • companies that rely on supplier certificates of analysis instead of their own identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk